The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 27, 2018
Filed:
Sep. 08, 2015
Applicant:
Merrimack Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Raghida Bukhalid, Melrose, MA (US);
Michael Feldhaus, Grantham, NH (US);
Anne Richard, Cambridge, MA (US);
Neeraj Kohli, Arlington, MA (US);
Eric Krauland, Lebanon, NH (US);
Jeffrey David Kearns, Arlington, MA (US);
Alexey A. Lugovskoy, Belmont, MA (US);
Ulrik Nielsen, Quincy, MA (US);
Assignee:
Merrimack Pharmaceuticals, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); C12Q 1/68 (2018.01); G01N 33/574 (2006.01); G01N 33/74 (2006.01); C07K 16/32 (2006.01); A61K 9/00 (2006.01); C07K 16/30 (2006.01); C07K 14/71 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12Q 1/686 (2013.01); G01N 33/57484 (2013.01); G01N 33/57496 (2013.01); G01N 33/74 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 14/71 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12Q 2600/106 (2013.01); G01N 2333/485 (2013.01); G01N 2333/495 (2013.01); G01N 2800/52 (2013.01);
Abstract
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.